Envoy Medical, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 76/100
What the filing says
Envoy Medical (market cap $12.7M) submitted the first of four modules of its modular PMA application to the FDA for its investigational fully implanted Acclaim cochlear implant on August 10, 2026. The company reported positive 12-month clinical data showing mean CNC word recognition score of 53.2% vs. 15.2% baseline (38 percentage point improvement). Q2 2026 net loss was $7.3M on $51K revenue; cash position improved to $19.7M (from $3.7M at year-end 2025) following a $30M equity raise in the period.
Why this rating
PMA submission and positive clinical data are material regulatory milestones for a pre-revenue medical device company at this scale. The $30M financing provides runway, but losses of ~$11.5M per half-year and modest cash burn trajectory create execution risk. Breakthrough designation suggests strong commercial potential if approved.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.